Understand the source comparison
Pinealon News 2026: Clinical Trial Comparison
The table below summarizes the two major pinealon clinical trials published in early 2026, comparing study design, dosing protocols, primary endpoints, and key findings. Russian Gerontological Research Center (2026) 120 adults aged 55–72 with subjective cognit
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below summarizes the two major pinealon clinical trials published in early 2026, comparing study design, dosing protocols, primary endpoints, and key findings.
- Russian Gerontological Research Center (2026)
- 120 adults aged 55–72 with subjective cognitive decline
- 20mg daily subcutaneous × 24 weeks
- RBANS total score change from baseline
- +12.4 points vs +1.8 placebo (p < 0.001); 18% improvement in delayed memory subdomain
- First human trial demonstrating statistically significant cognitive improvement with pinealon in aging population. Effect size comparable to approved dementia treatments
- University of Milan metabolic syndrome trial (2026)
- 80 adults aged 40–55 with metabolic syndrome
- 10mg daily subcutaneous × 16 weeks
- Cerebral blood flow velocity via transcranial Doppler
- +9% middle cerebral artery flow velocity vs baseline; no change in placebo
- Suggests vascular neuroprotection mechanism. Improved cerebral perfusion in at-risk population without formal cognitive testing
- ComparativeNote
- Different age groups and risk profiles
- Dosing varies 2:1 between trials
- One cognitive, one vascular endpoint
- Both trials showed physiological changes, not just subjective reports
- Pinealon demonstrates multiple mechanisms. Direct cognitive enhancement and cerebrovascular protection. Neither trial reported serious adverse events